The majority of companies selected to present at this year’s Mid-Atlantic Bio conference were startup firms focused on therapeutic drug development. The selections, which were made by a committee drawn from venture capital firms, reflect a trend toward funding drugs, not devices.
“Products seems to be more important than platforms these days,” said Todd Brady, a principal with the Princeton, N.J.-based venture firm Domain Associates. “Drug therapeutics are becoming more important than medical devices.”
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.